Long-term hormone therapy – the latest review from Cochrane
Printer-friendly versionThe latest Cochrane review on the evidence on hormonal therapy (HT) in peri- and postmenopausal women finds:
“HT significantly increases the risk of a coronary event, venous thrombo-embolism, stroke, breast cancer, gallbladder disease and death from lung cancer. Oestrogen-only HT has many of the same risks apart from risk of breast cancer. The only significant benefit found was a decrease in risk of fractures after long-term use for women with osteoporosis. It is generally recommended that HT only be used as management for osteoporosis in women at significant risk.”
Read the whole review.
The Canadian Women's Health Network and the Centres of Excellence for Women's Health program are financially supported by Health Canada through the Women's Health Contribution Program. The views herein do not necessarily represent the official policy of Health Canada.